Prostate Cancer Treatment Centre Receives Funding for Clini...(ed for use in the treatment ofprostate c...),Health

Date:11/14/2007

ed for use in the treatment of prostate cancer in Canada in June 2005. Can-Am HIFU urologists have been treating patients from Canada and abroad on an out-patient basis since March 2006. Currently the Sonablate(R) 500 is undergoing clinical trials in the United States and has not been approved for U.S. marketing by the FDA.

For more information on the study please contact Can-Am HIFU at 1 -877- 787-5906. For more information on HIFU with the Sonablate(R) 500, please visit http://www.internationalhifu.com

About Can-Am HIFU

Can-Am HIFU is a Canadian entity of USHIFU, LLC. The clinic, located in Toronto, was established in March 2006 and solely treats localized prostate cancer using HIFU with the Sonablate(R) 500. Can-Am HIFU physicians include Jack Barkin, MD; Laurence Klotz, MD; Sender Herschorn, MD; Neil Fleshner, MD; Michael Robinette, MD; Antonio Finelli, MD; and Sidney Radomski, MD.

About USHIFU

USHIFU, LLC is a development company headquartered in Charlotte, NC. USHIFU is the exclusive distributor of the Sonablate(R) 500 in North, South and Central America, the island nations of the Caribbean and South Africa. The company holds a minority ownership position in Focus Surgery Inc. of Indianapolis, the world leader in the development of HIFU products and the manufacturer of the Sonablate(R) 500 in conjunction with Misonix, Inc (MSON).

'/>"/>

SOURCE USHIFU, LLC Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2
Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy